title: [Eplerenone treatment in chronic central serous chorioretinopathy].
abstract: OBJECTIVE
  To evaluate the efficacy of eplerenone, a mineralocorticoid receptor antagonist, in the treatment of chronic central serous chorioretinopathy (CSCR).
  
  
  METHODS
  We conducted a retrospective study of 27 patients treated with eplerenone for chronic CSCR of at least 3 months duration. For each patient, visual acuity and macular OCT (central retinal thickness, height of foveal subretinal fluid (SRF), central choroidal thickness) were evaluated before treatment and at 1 month and 3 months. In the case of complete disappearance of SRF at 1 month, treatment was discontinued and follow-up was performed at 3 months.
  
  
  RESULTS
  Central retinal thickness was 371.6μm (266-573μm) before treatment. A clear decrease in retinal central thickness and height of SRF was observed at 1 month in 74% of patients (20 of 27 patients, central retinal thickness: 322.6μm at 1 month, P=0.01), with improvement of visual acuity in all of these patients. Follow-up at 3 months also found a decrease in SRF and central retinal thickness (294.3μm, P=0.002). Six patients had complete resolution of SRF at 1 month, without recurrence at 3 months. Six other patients had complete resolution of SRF at 3 months. No side effects requiring treatment discontinuation were observed.
  
  
  CONCLUSIONS
  In our study, eplerenone was associated with regression of central retinal thickness and height of SRF. Eplerenone appears to be a safe and effective treatment for chronic CSCR, with a probable mechanism of action on the pathophysiology of this disease.
authors.affiliation: Service d'ophtalmologie, hôpital de la Timone, AP-HM, 264, rue Saint-Pierre, 13005 Marseille, France. Electronic address: magali.sampo@ap-hm.fr.
authors.forename: M
authors.initials: M
authors.lastname: Sampo
authors.affiliation: Service d'ophtalmologie, hôpital Pierre-Paul-Riquet, CHU de Toulouse, place du Docteur-Baylac, TSA 40031, 31059 Toulouse cedex 9, France.
authors.forename: V
authors.initials: V
authors.lastname: Soler
authors.affiliation: Service d'ophtalmologie, hôpital Nord, AP-HM, chemin des Bourrely, 13915 Marseille cedex 20, France.
authors.forename: P
authors.initials: P
authors.lastname: Gascon
authors.affiliation: Service d'ophtalmologie, hôpital de la Timone, AP-HM, 264, rue Saint-Pierre, 13005 Marseille, France.
authors.forename: G
authors.initials: G
authors.lastname: Ho Wang Yin
authors.affiliation: Service d'ophtalmologie, hôpital de la Timone, AP-HM, 264, rue Saint-Pierre, 13005 Marseille, France.
authors.forename: L
authors.initials: L
authors.lastname: Hoffart
authors.affiliation: Service d'ophtalmologie, hôpital Nord, AP-HM, chemin des Bourrely, 13915 Marseille cedex 20, France.
authors.forename: D
authors.initials: D
authors.lastname: Denis
authors.affiliation: Service d'ophtalmologie, hôpital Nord, AP-HM, chemin des Bourrely, 13915 Marseille cedex 20, France.
authors.forename: F
authors.initials: F
authors.lastname: Matonti
mesh_terms: D000328:Adult; D000368:Aged; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy*; D002908:Chronic Disease; D000077545:Eplerenone; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D012189:Retrospective Studies; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone
keywords: Central serous chorioretinopathy; Choriorétinite séreuse centrale chronique; Eplerenone; Liquide sous-rétinien; Mineralocorticoid receptors; Récepteurs aux minéralocorticoïdes; Subretinal fluid; Traitement; Treatment; Éplérénone